SAN FRANCISCO (MarketWatch) -- Genentech Inc. on Monday said that a Phase I/II clinical study of patients with wet age-related macular degeneration using the investigational anti-VEGF drug Lucentis in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback